Psychedelics such as LSD, MDMA (ecstasy), and psilocybin are being tested in clinical trials for treatment of PTSD, obsessive-compulsive disorder, depression, and anxiety. The FDA has granted breakthrough therapy status to certain psychedelic treatments to expedite development and potential approval. These substances are generally physically well-tolerated and non-addictive, making them promising adjunct therapies. Flashbacks—reoccurring drug-like experiences after acute effects—have been reported for many psychoactive agents, with incidence estimates ranging widely from around 10 percent to as high as 75 percent in historical reports. Flashbacks are usually transient and generally benign for most users, and LSD has produced more reports than MDMA, cannabis, or psilocybin. The DSM-5 estimates one in 25 hallucinogen users will experience flashbacks.
Psychedelic-assisted therapy combines the use of psychedelic substances with psychotherapy for individuals suffering from post- traumatic stress disorder, obsessive-compulsive disorder, depression, or anxiety. Recently, the FDA granted "breakthrough therapy" status to certain psychedelic treatments, expediting their development and potential approval. LSD, MDMA (ecstasy), and psilocybin are increasingly being tested in clinical trials for their therapeutic potential. for treating aspects of mental disorders.
LSD-induced flashbacks were regularly recorded in the 1950s when the drug was first tested as a psychiatric treatment. Despite this long history of occurrence, the phenomena are still poorly described or understood. Making the problem more complicated is the fact that the reported incidences vary widely, between 15 to 75 percent of all users being affected. Overall, more flashbacks are reported after LSD use than for MDMA, cannabis, or psilocybin.
Collection
[
|
...
]